Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25375053 | 1.00 | DUT (0.41) | DUT | |
| SCHEMBL25373236 | 1.00 | DUT (0.41) | DUT | |
| SCHEMBL15345823 | 1.00 | DUT (0.41) | DUT | |
| SCHEMBL25378318 | 0.88 | DUT (0.36) | DUT | |
| SCHEMBL740880 | 0.86 | DUT (0.34) | DUT | |
| SCHEMBL11580466 | 0.81 | DUT (0.42) | DUT | |
| SCHEMBL20088142 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL30612911 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL26510570 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL29284186 | 0.80 | DUT (0.41) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841402-B1 | LABELLED QUINOXALINE DERIVATIVES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-11-30 | — | — | EP | disclosed |
| US-20150079000-A1 | Labelled Quinoxaline Derivatives as Multimodal Radiopharmaceuticals and Their Precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-03-19 | — | — | US | disclosed |
| US-20150079000-A1 | Labelled Quinoxaline Derivatives as Multimodal Radiopharmaceuticals and Their Precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-03-19 | — | — | US | disclosed |
| EP-2841402-A1 | LABELLED QUINOXALINE DERIVATIVES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013160808-A1 | LABELLED QUINOXALINE DERIVATIVES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2013-10-31 | — | — | WO | disclosed |
| EP-2657213-A1 | Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors | Institut National de la Santé et de la Recherche Medicale (FR) | 2013-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079000-A1 | Labelled Quinoxaline Derivatives as Multimodal Radiopharmaceuticals and Their Precursors | HRH3, SSTR3, MC3R | DUT 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.